JP2013520681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520681A5 JP2013520681A5 JP2012555001A JP2012555001A JP2013520681A5 JP 2013520681 A5 JP2013520681 A5 JP 2013520681A5 JP 2012555001 A JP2012555001 A JP 2012555001A JP 2012555001 A JP2012555001 A JP 2012555001A JP 2013520681 A5 JP2013520681 A5 JP 2013520681A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- mass spectrum
- treatment
- combination
- predetermined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 238000000034 method Methods 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 17
- 238000001819 mass spectrum Methods 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 238000011282 treatment Methods 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 14
- 239000008280 blood Substances 0.000 claims 10
- 210000004369 blood Anatomy 0.000 claims 10
- 229940111134 coxibs Drugs 0.000 claims 10
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 10
- 238000001228 spectrum Methods 0.000 claims 8
- 238000007635 classification algorithm Methods 0.000 claims 7
- 102000003923 Protein Kinase C Human genes 0.000 claims 6
- 108090000315 Protein Kinase C Proteins 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 229940121647 egfr inhibitor Drugs 0.000 claims 4
- 102000043136 MAP kinase family Human genes 0.000 claims 3
- 108091054455 MAP kinase family Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000038030 PI3Ks Human genes 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 229960000371 rofecoxib Drugs 0.000 claims 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940124638 COX inhibitor Drugs 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000018883 protein targeting Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33893810P | 2010-02-24 | 2010-02-24 | |
| US61/338,938 | 2010-02-24 | ||
| PCT/US2011/000323 WO2011106084A1 (en) | 2010-02-24 | 2011-02-22 | Cancer patient selection for administration of therapeutic agents using mass spectral analysis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015121648A Division JP2015222257A (ja) | 2010-02-24 | 2015-06-17 | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520681A JP2013520681A (ja) | 2013-06-06 |
| JP2013520681A5 true JP2013520681A5 (enExample) | 2014-05-08 |
Family
ID=44477214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555001A Withdrawn JP2013520681A (ja) | 2010-02-24 | 2011-02-22 | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
| JP2015121648A Withdrawn JP2015222257A (ja) | 2010-02-24 | 2015-06-17 | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015121648A Withdrawn JP2015222257A (ja) | 2010-02-24 | 2015-06-17 | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110208433A1 (enExample) |
| EP (1) | EP2539704A4 (enExample) |
| JP (2) | JP2013520681A (enExample) |
| KR (1) | KR101556726B1 (enExample) |
| CN (1) | CN102770760A (enExample) |
| AU (2) | AU2011219069C1 (enExample) |
| CA (1) | CA2790928A1 (enExample) |
| TW (1) | TW201142292A (enExample) |
| WO (1) | WO2011106084A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014505257A (ja) * | 2011-01-28 | 2014-02-27 | バイオデシックス・インコーポレイテッド | ホルモン療法および組み合わせ療法のための転移性乳癌患者の選択の予測試験 |
| EP3096142A3 (en) * | 2011-04-29 | 2017-03-08 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| WO2013180818A2 (en) | 2012-05-29 | 2013-12-05 | Biodesix, Inc. | Deep-maldi tof mass spectrometry of complex biological samples, e.g., serum, and uses thereof |
| SG11201408652SA (en) | 2012-06-26 | 2015-01-29 | Biodesix Inc | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| WO2014007859A1 (en) * | 2012-07-05 | 2014-01-09 | Biodesix, Inc. | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents |
| US9211314B2 (en) | 2014-04-04 | 2015-12-15 | Biodesix, Inc. | Treatment selection for lung cancer patients using mass spectrum of blood-based sample |
| WO2015157109A1 (en) * | 2014-04-08 | 2015-10-15 | Biodesix, Inc. | Egfr and hgf inhibitor therapy for lung cancer |
| WO2016054031A1 (en) * | 2014-10-02 | 2016-04-07 | Biodesix, Inc. | Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample |
| US11594403B1 (en) | 2014-12-03 | 2023-02-28 | Biodesix Inc. | Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample |
| US10037874B2 (en) | 2014-12-03 | 2018-07-31 | Biodesix, Inc. | Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry |
| US11152197B2 (en) * | 2015-06-24 | 2021-10-19 | City University Of Hong Kong | Method of determining cell cycle stage distribution of cells |
| CN112710723B (zh) * | 2015-07-13 | 2024-11-12 | 佰欧迪塞克斯公司 | 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法 |
| US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
| CN106596824A (zh) * | 2016-12-30 | 2017-04-26 | 广州中大南沙科技创新产业园有限公司 | 一种lc‑ms/ms法检测血浆中沙利度胺的方法 |
| CN110383069A (zh) | 2017-01-05 | 2019-10-25 | 佰欧迪塞克斯公司 | 用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法 |
| CN109212042B (zh) * | 2017-06-30 | 2022-03-04 | 齐鲁制药有限公司 | 一种采用液质联用法测定盐酸培唑帕尼基因毒性杂质的分析方法 |
| KR102633621B1 (ko) | 2017-09-01 | 2024-02-05 | 벤 바이오사이언시스 코포레이션 | 진단 및 치료 모니터링용 바이오마커로서의 당펩티드의 식별 및 용도 |
| EP3724885A2 (en) | 2017-12-15 | 2020-10-21 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| WO2019190732A1 (en) * | 2018-03-29 | 2019-10-03 | Biodesix, Inc. | Apparatus and method for identification of primary immune resistance in cancer patients |
| WO2020019095A1 (es) * | 2018-07-26 | 2020-01-30 | Universidad Católica Del Maule | Proteína rage (receptor de productos finales de glicacíon avanzada) como biomarcador de sensibilidad tumoral y evaluacion de terapia radiologica y radiomimética |
| CN119139478A (zh) * | 2024-10-11 | 2024-12-17 | 首都医科大学附属北京胸科医院 | 一种治疗anxa6+egfr突变的肺腺癌的组合物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4802102A (en) * | 1987-07-15 | 1989-01-31 | Hewlett-Packard Company | Baseline correction for chromatography |
| US5291426A (en) * | 1991-02-27 | 1994-03-01 | The Perkin-Elmer Corporation | Method of correcting spectral data for background |
| ES2070739B1 (es) * | 1993-04-30 | 1997-06-01 | Alcatel Standard Electrica | Dispositivo de conversion de interfaces. |
| US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| US6017693A (en) * | 1994-03-14 | 2000-01-25 | University Of Washington | Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry |
| US5672869A (en) * | 1996-04-03 | 1997-09-30 | Eastman Kodak Company | Noise and background reduction method for component detection in chromatography/spectrometry |
| US6253162B1 (en) * | 1999-04-07 | 2001-06-26 | Battelle Memorial Institute | Method of identifying features in indexed data |
| IL153189A0 (en) * | 2000-06-19 | 2003-06-24 | Correlogic Systems Inc | Heuristic method of classification |
| CA2414610A1 (en) * | 2000-07-13 | 2002-01-24 | Medi-Physics, Inc. | Diagnostic procedures using 129xe spectroscopy characteristic chemical shift to detect pathology in vivo |
| SG144731A1 (en) * | 2000-07-18 | 2008-08-28 | Correlogic Systems Inc | A process for discriminating between biological states based on hidden patterns from biological data |
| AU2002241535B2 (en) * | 2000-11-16 | 2006-05-18 | Ciphergen Biosystems, Inc. | Method for analyzing mass spectra |
| US20020119490A1 (en) * | 2000-12-26 | 2002-08-29 | Aebersold Ruedi H. | Methods for rapid and quantitative proteome analysis |
| US20020115056A1 (en) * | 2000-12-26 | 2002-08-22 | Goodlett David R. | Rapid and quantitative proteome analysis and related methods |
| US6829539B2 (en) * | 2001-04-13 | 2004-12-07 | The Institute For Systems Biology | Methods for quantification and de novo polypeptide sequencing by mass spectrometry |
| US6849121B1 (en) * | 2001-04-24 | 2005-02-01 | The United States Of America As Represented By The Secretary Of The Air Force | Growth of uniform crystals |
| US7314717B2 (en) * | 2001-04-30 | 2008-01-01 | Nanogen Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons |
| US7113896B2 (en) * | 2001-05-11 | 2006-09-26 | Zhen Zhang | System and methods for processing biological expression data |
| US6675106B1 (en) * | 2001-06-01 | 2004-01-06 | Sandia Corporation | Method of multivariate spectral analysis |
| US7112408B2 (en) * | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| WO2003006951A2 (en) * | 2001-07-13 | 2003-01-23 | Syngenta Participations Ag | System and method of determining proteomic differences |
| US7016884B2 (en) * | 2002-06-27 | 2006-03-21 | Microsoft Corporation | Probability estimate for K-nearest neighbor |
| WO2004019003A2 (en) * | 2002-08-23 | 2004-03-04 | Efeckta Technologies Corporation | Image processing of mass spectrometry data for using at multiple resolutions |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| US6906320B2 (en) * | 2003-04-02 | 2005-06-14 | Merck & Co., Inc. | Mass spectrometry data analysis techniques |
| JP2007506442A (ja) * | 2003-05-30 | 2007-03-22 | ゲノミック ヘルス， インコーポレイテッド | Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー |
| US20050267689A1 (en) * | 2003-07-07 | 2005-12-01 | Maxim Tsypin | Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications |
| US20050048547A1 (en) * | 2003-07-17 | 2005-03-03 | Hongyu Zhao | Classification of disease states using mass spectrometry data |
| SG145705A1 (en) * | 2003-08-01 | 2008-09-29 | Correlogic Systems Inc | Multiple high-resolution serum proteomic features for ovarian cancer detection |
| EP1709442A4 (en) * | 2003-12-11 | 2010-01-20 | Correlogic Systems Inc | METHOD FOR DIAGNOSING BIOLOGICAL CONDITIONS BY USING A CENTRALIZED ADAPTIVE MODEL AND SAMPLE PREPARATION |
| ES2244326B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
| JP2008501654A (ja) * | 2004-06-03 | 2008-01-24 | エフ．ホフマン−ラ ロシュ アーゲー | シスプラチンとｅｇｆｒ阻害剤を用いた治療 |
| US20060029574A1 (en) * | 2004-08-06 | 2006-02-09 | Board Of Regents, The University Of Texas System | Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity |
| SI1948180T1 (sl) * | 2005-11-11 | 2013-06-28 | Boehringer Ingelheim International Gmbh | Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje |
| US7858389B2 (en) * | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway |
| US7906342B2 (en) * | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
| US7858390B2 (en) * | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| US7867775B2 (en) * | 2006-03-31 | 2011-01-11 | Biodesix, Inc. | Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway |
| JP2010508512A (ja) * | 2006-10-27 | 2010-03-18 | ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア | 転移性結腸直腸癌のアッセイ |
| CN101201355A (zh) * | 2006-12-15 | 2008-06-18 | 许洋 | 免疫组质谱检测个体化肿瘤生物标志及疗效试剂盒和方法 |
| ES2412432T3 (es) * | 2007-02-27 | 2013-07-11 | Nuclea Biomarkers Llc | Método para predecir la respuesta de pacientes de nsclc al tratamiento mediante un inhibidor de egfr-tk |
| CN101329346A (zh) * | 2007-06-18 | 2008-12-24 | 许洋 | 检测乳腺癌特征蛋白的优化质谱模型及其制备方法和应用 |
| WO2009036123A1 (en) * | 2007-09-11 | 2009-03-19 | Cancer Prevention And Cure, Ltd. | Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues |
| CN101836991B (zh) * | 2009-03-19 | 2013-05-22 | 鼎泓国际投资（香港）有限公司 | 含有索拉非尼、cMet抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
| WO2014007859A1 (en) * | 2012-07-05 | 2014-01-09 | Biodesix, Inc. | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents |
-
2011
- 2011-02-22 AU AU2011219069A patent/AU2011219069C1/en not_active Ceased
- 2011-02-22 US US12/932,295 patent/US20110208433A1/en not_active Abandoned
- 2011-02-22 KR KR1020127024976A patent/KR101556726B1/ko not_active Expired - Fee Related
- 2011-02-22 CN CN2011800110326A patent/CN102770760A/zh active Pending
- 2011-02-22 WO PCT/US2011/000323 patent/WO2011106084A1/en not_active Ceased
- 2011-02-22 JP JP2012555001A patent/JP2013520681A/ja not_active Withdrawn
- 2011-02-22 EP EP11747809.9A patent/EP2539704A4/en not_active Withdrawn
- 2011-02-22 CA CA2790928A patent/CA2790928A1/en not_active Abandoned
- 2011-02-24 TW TW100106286A patent/TW201142292A/zh unknown
-
2014
- 2014-05-19 AU AU2014202716A patent/AU2014202716B2/en not_active Expired - Fee Related
- 2014-06-04 US US14/295,783 patent/US20140284468A1/en not_active Abandoned
-
2015
- 2015-06-17 JP JP2015121648A patent/JP2015222257A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520681A5 (enExample) | ||
| Loboda et al. | A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors | |
| He et al. | The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells | |
| Gagliano et al. | mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids | |
| Zhu et al. | UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma | |
| Li et al. | Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy | |
| Tseng et al. | Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| Lee et al. | Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival | |
| Yu et al. | Tryptophan metabolism in digestive system tumors: unraveling the pathways and implications | |
| Xiao et al. | Over-expression of TRPM8 is associated with poor prognosis in urothelial carcinoma of bladder | |
| JP2015514712A5 (ja) | 発癌物質によって誘発される癌の治療における使用のためのｃｕｒａｘｉｎ | |
| Chen et al. | Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer | |
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target | |
| Naruse et al. | Therapeutic implication of mTORC2 in oral squamous cell carcinoma | |
| WO2013112881A1 (en) | Mct protein inhibitor-related prognostic and therapeutic methods | |
| JP2010510495A5 (enExample) | ||
| JP2013526863A5 (enExample) | ||
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| RU2016125005A (ru) | Способы модулирования различных биомаркеров при помощи кураксинов | |
| Suspitsin et al. | Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules? | |
| Lam et al. | Sleep apnoea and immune regulation: The story is only beginning. | |
| RU2012131752A (ru) | Способ прогнозирования терапевтических эффектов химиотерапии у пациентов с печеночно-клеточной карциномой | |
| Zhao et al. | P2. 03-23 MicroRNA-30e Inhibits Cell Proliferation and Invasion in Non-Small Cell Lung Cancer via Directly Targeting SOX9 |